Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Convertible Debt (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Convertible Debt for 10 consecutive years, with $228.6 million as the latest value for Q1 2025.

  • Quarterly Convertible Debt rose 0.59% to $228.6 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $228.6 million through Mar 2025, up 0.59% year-over-year, with the annual reading at $228.2 million for FY2024, 0.59% up from the prior year.
  • Convertible Debt hit $228.6 million in Q1 2025 for Coherus Oncology, roughly flat from $228.2 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $332.8 million in Q4 2021 to a low of $223.3 million in Q1 2021.
  • Historically, Convertible Debt has averaged $232.3 million across 5 years, with a median of $226.2 million in 2023.
  • Biggest five-year swings in Convertible Debt: skyrocketed 316.56% in 2021 and later crashed 32.21% in 2022.
  • Year by year, Convertible Debt stood at $332.8 million in 2021, then plummeted by 32.21% to $225.6 million in 2022, then increased by 0.58% to $226.9 million in 2023, then grew by 0.59% to $228.2 million in 2024, then rose by 0.15% to $228.6 million in 2025.
  • Business Quant data shows Convertible Debt for CHRS at $228.6 million in Q1 2025, $228.2 million in Q4 2024, and $227.9 million in Q3 2024.